HomeCompareFSEI vs PFE

FSEI vs PFE: Dividend Comparison 2026

FSEI yields 399999.98% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FSEI wins by $5.011117025842008e+32M in total portfolio value
10 years
FSEI
FSEI
● Live price
399999.98%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011117025842008e+32M
Annual income
$500,865,383,069,816,700,000,000,000,000,000,000,000.00
Full FSEI calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — FSEI vs PFE

📍 FSEI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFSEIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FSEI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FSEI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FSEI
Annual income on $10K today (after 15% tax)
$33,999,998.64/yr
After 10yr DRIP, annual income (after tax)
$425,735,575,609,344,150,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, FSEI beats the other by $425,735,575,609,344,150,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FSEI + PFE for your $10,000?

FSEI: 50%PFE: 50%
100% PFE50/50100% FSEI
Portfolio after 10yr
$2.505558512921004e+32M
Annual income
$250,432,691,534,908,340,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

FSEI
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FSEI buys
0
PFE buys
0
No recent congressional trades found for FSEI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFSEIPFE
Forward yield399999.98%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.011117025842008e+32M$51.1K
Annual income after 10y$500,865,383,069,816,700,000,000,000,000,000,000,000.00$27,210.54
Total dividends collected$5.010955813019811e+32M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FSEI vs PFE ($10,000, DRIP)

YearFSEI PortfolioFSEI Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$40,010,698$39,999,998.40$9,161$701.38+$40.00MFSEI
2$149,615,509,763$149,572,698,316.16$8,610$859.79+$149615.50MFSEI
3$522,879,989,997,580$522,719,901,402,132.94$8,366$1,081.25+$522879989.99MFSEI
4$1,707,862,716,112,105,200$1,707,303,234,522,807,600.00$8,483$1,405.66+$1707862716112.10MFSEI
5$5,213,508,360,464,628,000,000$5,211,680,947,358,388,000,000.00$9,084$1,907.24+$5213508360464628.00MFSEI
6$14,874,215,489,735,566,000,000,000$14,868,637,035,789,870,000,000,000.00$10,418$2,732.78+$14874215489735565312.00MFSEI
7$39,661,185,132,588,870,000,000,000,000$39,645,269,722,014,850,000,000,000,000.00$13,007$4,193.56+$3.966118513258887e+22MFSEI
8$98,838,404,732,879,950,000,000,000,000,000$98,795,967,264,788,080,000,000,000,000,000.00$18,010$7,005.87+$9.883840473287995e+25MFSEI
9$230,205,153,629,969,500,000,000,000,000,000,000$230,099,396,536,905,300,000,000,000,000,000,000.00$28,216$12,979.89+$2.302051536299695e+29MFSEI
10$501,111,702,584,200,800,000,000,000,000,000,000,000$500,865,383,069,816,700,000,000,000,000,000,000,000.00$51,081$27,210.54+$5.011117025842008e+32MFSEI

FSEI vs PFE: Complete Analysis 2026

FSEIStock

In May 2001, FIRST SEISMIC Corporation executed a letter of intent with Global Geo Services ASA, a Norwegian company (GGS), pursuant to which GGS proposed to acquire First Seismic. As of December 31, 1999, FIRST SEISMIC Corporation provided various geo-scientific and complementary services that were used to develop opportunities in the oil and gas business worldwide. It owned and brokered seismic data and a range of geo-scientific information primarily used by its customers in upstream oil and gas exploration and production efforts. The company used portions of this geological and seismic information to geo-technically identify and promote exploration projects to oil company investors. In addition, through its wholly owned subsidiary, the company also took an ownership position in some of the upstream oil and natural gas production opportunities. The company is based in Houston, Texas.

Full FSEI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this FSEI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FSEI vs SCHDFSEI vs JEPIFSEI vs OFSEI vs KOFSEI vs MAINFSEI vs JNJFSEI vs MRKFSEI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.